BridgeBio Pharma, Inc. (BBIO) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
BridgeBio Pharma, Inc. (BBIO) Bundle
Looking to determine the intrinsic value of BridgeBio Pharma, Inc.? Our (BBIO) DCF Calculator integrates real-world data with comprehensive customization features, allowing you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.6 | 8.2 | 69.7 | 77.6 | 9.3 | 8.0 | 6.9 | 5.9 | 5.1 | 4.4 |
| Revenue Growth, % | 0 | -79.66 | 745.14 | 11.38 | -88.02 | -14.08 | -14.08 | -14.08 | -14.08 | -14.08 |
| EBITDA | -279.8 | -465.7 | -533.8 | -397.4 | -565.5 | -8.0 | -6.9 | -5.9 | -5.1 | -4.4 |
| EBITDA, % | -689.89 | -5646.08 | -765.73 | -511.85 | -6078.34 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .9 | 3.1 | 5.8 | 6.8 | 6.5 | 2.0 | 1.7 | 1.5 | 1.3 | 1.1 |
| Depreciation, % | 2.12 | 37.43 | 8.38 | 8.72 | 69.81 | 25.29 | 25.29 | 25.29 | 25.29 | 25.29 |
| EBIT | -280.7 | -468.8 | -539.7 | -404.2 | -572.0 | -8.0 | -6.9 | -5.9 | -5.1 | -4.4 |
| EBIT, % | -692.01 | -5683.51 | -774.11 | -520.57 | -6148.15 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 577.1 | 607.1 | 787.5 | 428.3 | 434.9 | 8.0 | 6.9 | 5.9 | 5.1 | 4.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 19.7 | 17.1 | 1.8 | 1.1 | .9 | .8 | .7 | .6 |
| Account Receivables, % | 0 | 0 | 28.33 | 22 | 18.82 | 13.83 | 13.83 | 13.83 | 13.83 | 13.83 |
| Inventories | .0 | .0 | -68.9 | 37.9 | .0 | -.8 | -.7 | -.6 | -.5 | -.4 |
| Inventories, % | 0 | 0 | -98.83 | 48.85 | 0 | -10 | -10 | -10 | -10 | -10 |
| Accounts Payable | 8.9 | 8.9 | 11.9 | 11.6 | 10.7 | 4.1 | 3.5 | 3.0 | 2.6 | 2.2 |
| Accounts Payable, % | 21.82 | 108.44 | 17.05 | 14.89 | 114.53 | 50.75 | 50.75 | 50.75 | 50.75 | 50.75 |
| Capital Expenditure | -5.1 | -7.5 | -48.2 | -6.3 | -1.3 | -3.1 | -2.7 | -2.3 | -2.0 | -1.7 |
| Capital Expenditure, % | -12.67 | -91.14 | -69.2 | -8.14 | -14.04 | -39.04 | -39.04 | -39.04 | -39.04 | -39.04 |
| Tax Rate, % | 1.54 | 1.54 | 1.54 | 1.54 | 1.54 | 1.54 | 1.54 | 1.54 | 1.54 | 1.54 |
| EBITAT | -253.3 | -448.8 | -588.3 | -412.0 | -563.2 | -7.7 | -6.7 | -5.7 | -4.9 | -4.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -248.7 | -453.2 | -578.6 | -516.0 | -505.6 | -14.0 | -8.1 | -7.0 | -6.0 | -5.2 |
| WACC, % | 8.09 | 8.17 | 8.22 | 8.22 | 8.2 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -33.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -5 | |||||||||
| Terminal Value | -85 | |||||||||
| Present Terminal Value | -57 | |||||||||
| Enterprise Value | -91 | |||||||||
| Net Debt | 1,364 | |||||||||
| Equity Value | -1,455 | |||||||||
| Diluted Shares Outstanding, MM | 163 | |||||||||
| Equity Value Per Share | -8.94 |
What You Will Get
- Real BridgeBio Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for BridgeBio Pharma, Inc. (BBIO).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on BridgeBio's fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to BridgeBio Pharma, Inc. (BBIO).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your assessments.
Key Features
- Comprehensive BridgeBio Financials: Access precise historical data and future forecasts tailored for [BBIO].
- Adjustable Forecast Parameters: Modify highlighted cells for metrics like WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to effectively display your valuation insights.
- Suitable for All Levels: An intuitive design crafted for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered BridgeBio Pharma, Inc. (BBIO) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for BridgeBio Pharma, Inc. (BBIO)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for BridgeBio Pharma, Inc. (BBIO)?
- Designed for Experts: A sophisticated tool tailored for analysts, investors, and biotech professionals.
- Accurate Data: BridgeBio’s historical and projected financials integrated for reliability.
- Flexible Scenario Analysis: Easily test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Detailed instructions to assist you throughout the calculation process.
Who Should Use This Product?
- Investors: Accurately estimate BridgeBio Pharma, Inc.'s (BBIO) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis of BridgeBio Pharma, Inc. (BBIO).
- Consultants: Quickly modify the template for valuation reports tailored to BridgeBio Pharma, Inc. (BBIO) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like BridgeBio Pharma, Inc. (BBIO).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies specific to the biotech industry.
What the Template Contains
- Pre-Filled DCF Model: BridgeBio Pharma’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate BridgeBio Pharma’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.